Got Milk? Roche to Apply PureTech Exosomes Platform in $1B+ Collaboration

Roche will work to enable oral administration of its antisense oligonucleotide platform using PureTech Health’s milk-derived exosome technology, through a collaboration that PureTech said today could generate for it more than $1 billion.Under the multi-year collaboration, Roche will study applying PureTech’s milk exosomes technology, which is designed to facilitate oral delivery of macromolecules such as nucleic acids and peptides, as well as complex small molecules.PureTech reasons